The mechanisms responsible for skin lesions during acute graft-vs.-host disease (aGVHD) after allogeneic bone marrow transplantation (BMT) are poorly understood. The exact role of various effector cell populations and "major" (particularly HLA-DP) or "minor" antigens as target molecules is not known. To investigate the nature of cells responsible for tissue injury, we cultured T cells from skin biopsy first with interleukin 2 (IL-2) alone and then in polyclonal activation conditions to avoid in vitro antigenic sensitization before specificity testing. We applied this method to two biopsies performed during aGVHD after semiallogeneic BMT and obtained cytotoxic T cells against four graft mismatches: CD8+ T cells against HLA-A2.2 and HLA-B27 and CD4+ T cells against HLADPlO and HLA-DP401. This demonstrates that T cells with documented specificity can be obtained from an aGVHD lesion without antigenic selection. Moreover, these data directly implicate DP as a potential target antigen for aGVHD. (J. Clin. Invest. 1993. 91:12-20.)
Introduction
Although T cells have not been directly implicated in the etiology of acute graft-vs.-host disease (aGVHD)' in humans, their importance in this process is strongly suggested by the following observations: T cell depletion is efficient in preventing aGVHD (1) (2) (3) (4) ; a correlation exists between the number of engrafted T cells and the severity of aGVHD (5) (6) (7) (8) (9) , as well as between anti-host-cytotoxic T lymphocyte precursor frequency (pCTL) and the occurrence of aGVHD (10) ; and T cells are present at the site of aGVHD lesions (1 1-16) . However, the nature of the molecular and cellular targets and the effector lymphocytes responsible for target damage remain to be determined. One interesting feature ofGVHD is the specificity ofthe lesion site (mainly digestive epithelia and epidermis), in that the mechanisms by which nonlymphoid target tissues are selected for immune-mediated damage are poorly understood. The fact that T cells can distinguish between allogeneic major histocompatibility complex products on different cell types ( 17) , and that in GVHD a high number of nonepithelial cells expressing recipient class II antigens in many tissues are not affected by GVHD (18) , raises the question of T-target intera,tion during GVHD, either through "minor" or "major" antigei-ic disparities. However, as tissue specificity is always observed regardless of the genetic combination, it is likely that allorecognition through the T cell receptor cannot fully account for epithelium targeting.
Goulmy and co-workers have documented the presence of anti-host-specific CTL among recipient peripheral blood lymphocytes (PBL). These CTL, probably directed at minor antigens, can lyse host PBL isolated before grafting ( 19) . However, the same group has also detected these CTL in PBL ofpatients with no clinical signs of GVHD (20) . This latter observation suggests that PBL studies, particularly when performed after several in vitro stimulations with host cells, do not reflect what takes place at a GVHD lesion site. Other authors have obtained T cells from skin lesions either by stimulation at the beginning of the culture with allogeneic B lymphoblastoid cell lines (BLCL) sharing HLA antigens with host cells (21 ) or, after an initial culture period with IL2 alone, by a coculture with host BLCL before testing (22) . In both cases, anti-host cells were obtained, but no antigenic specificity could be defined in these HLA-identical situations.
Our goal in this work was to characterize T cells from a GVHD lesion site which were only sensitized in vivo against the host. We therefore investigated lymphoid populations infiltrating the skin from two patients during aGVHD after allogeneic haploidentical bone marrow transplantation (BMT Punch biopsies (4 mm) were taken and frozen in liquid nitrogen. Sections (3 Mum) were cut and immersed for 10 min in acetone and then washed in PBS for 10 min. After 30 min ofincubation at 37°C with the appropriate mAb dilution, sections were washed in PBS. Fluoresceinconjugated goat anti-mouse IgG (Bio-Atlantique, Nantes) diluted 1/5 was then applied for 30 min at 37°C followed by washing in PBS. Sections were examined at x320 using a Zeiss microscope. Percentages were determined among 100 propidium iodide-positive cells in at least three different fields.
Cytotoxic assay Cytotoxic activity was tested using a standard 5"Cr release assay: Target cells were labeled with 100 MCi 5'Cr for 2 h at 37°C, washed three times, and then plated at the indicated effector/target cell ratio in a 96-well round-bottomed plate. After 4 h ofincubation at 37°C, 100 MAl ofsupernatant from each well was removed and counted in a gamma scintillation counter. Each test was performed in triplicate. Results are expressed as percentage of lysis, according to the following formula: (experimental release -spontaneous release)/(maximal release -spontaneous release) x 100, where experimental release represents mean counts per minute released from the target cell in the presence of effector cells, spontaneous release that from target incubated without effectors and maximal release that from target incubated with 1% cetavlon.
Proliferation assay I04 resting T cells were cocultured for 4 
Southern blot analysis
Filter hybridization. After digestion with Eco RI or Hind III, 15 ,ug of genomic DNA samples were size-fractionated by electrophoresis through 1% agarose gels. Southern blotting was performed using a vacuum blotting system (LKB-Pharmacia, St. Quentin en Yvelines, France) on Hybond N+ filter (Amersham, Les Ullis, France) according to the supplier's instructions. Hybridization, washing, and autoradiographies were performed as previously described (23) with 32p multiprimed probe.
Probes. The Jy probe, pH60, containing the 700 base-pair HindIIIEcoRI fragment from M 13H60, includes the Jly1 segment (24, 25).
This fragment cross-hybridizes with J'y2 but not with JP, JPI, or JP2. The Cj3 probe IBIOBBI corresponds to the C,BI fragment and cross-hybridizes with C#2 (26) .
Results
Ten biopsies from different clinical situations were studied. T cells could be obtained only when GVHD was confirmed histologically and clinically, strongly suggesting that they were able to grow in vitro in our culture conditions only when preactivated in vivo. In the two cases presented, T cell proliferation started as early as 3 d after initiation of the culture.
Patient 1 I. Generation ofthe skin biopsy-derived (SBD) T cell line. As only the recipient was HLA-A2+, HLA-A2-specific mAbs were used to determine whether SBD-T cells were of donor origin, i.e., HLA-A2- (Fig. 1) . At day 13, the SBD-T cell line consisted mostly of CD4+, TCR a/,8+ T cells. This was in sharp contrast with phenotyping results obtained from a contiguous biopsy, indicating that most (70%) infiltrating lymphocytes were CD8+ (data not shown). This suggested that CD8+ cells were rapidly overgrown by CD4+ cells during the bulk culture period.
IL SBD T cell line specificity. Initial testing of this bulk culture demonstrated both specific proliferation and cytotoxicity against host BLCL but no lymphokine-activated killer activ- 14 Gaschet et al. ity against the DAUDI cell line (Fig. 2) . When antibodies against class I (W632), class II (TU39), DR (GSP41), DQ (Leu-10), and DP (B7.2 1) were added to the assay, proliferation was abrogated by TU39 and B7.21 mAb only (Fig. 3 ). Cell line specificity was then studied using the BLCL panel described in Table I . When tested for cytotoxic activity against 14 BLCL bearing different HLA antigens, the SBD-cell line demonstrated its cytotoxic potential only against host (HLA-DPIOI, 1901), J (BM9: HLA-DPIOI, 101), and P (VAVY: HLA-DP 101, 101) BLCL (Fig. 4, top) . No significant cytotoxicity was observed against any other BLCL tested. Specific recognition of HLA-DP101 + BLCL by the SBD T-cell line was confirmed by proliferation assays using four HLA-DP101+ and 4 HLA-DP101 -stimulator cells (Fig. 4, bottom) . III. Analysis ofcell-line polyclonality and Tcell clone specificity. The (Fig. 8, top) . Although CD8+ cells were overgrown by CD4+ in the bulk culture as in the case of patient 1, early cloning allowed us to obtain a CD8 + clone which specifically recognized the HLA-B27+ BLCL Q (WT24) and T (BTB) (Fig. 8, bottom) . Because HOM2 was of female and WT24 and BTB of male origin, these data indicate as in the previous case that the CD8 + cells were not restricted to HLA-B27 of male origin. Among the CD4+ clones characterized so far, two clones (CD4-1 and CD4-2) strongly proliferated when cocultured with irradiated BLCL R (BM 14). This proliferation was blocked by mAbs 2D6 (anti-DP/DR), and B7.21 (anti-DP) but not by mAbs Leu-10 or IA3 (anti-DQ) or GSP41 (anti-DR) (Fig. 9, top) . When tested on panel BLCL, these two clones proved specific for BLCL G (DP301 /401), R (DP401), S (DP401 ), but not for D (DP202), A (DP402), or P (DP 101) (Fig. 9, bottom) . Taken together, these results indicate that these CD4+ clones recognized HLA-DP40 1. Table I . iscussion ur data demonstrate the presence ofT cells with defined anti-)st specificity at a GVHD lesion site and indicate for the first me the direct involvement of DP antigens as a potential target r acute GVHD. More generally, they demonstrate the possility of obtaining specific T cells from aGVHD lesions after )nspecific in vitro expansion of SBD lymphocytes, a techque which avoids the bias of in vitro sensitization. Because vese cells were isolated from a lesion rather than from the riphery and were never restimulated in vitro with host cells fore specificity assays, their specific anti-host reactivity prob-)ly reflects in vivo preselection. This is supported by the fact vat we obtained six cell lines from 10 biopsies studied in differt clinical situations. In the four cases in which the culture was gative, GVHD diagnosis was not confirmed. In the two cases -esented, T cells started growing out of the biopsy within 3 d ter initiation of the culture. These results are comparable to vose obtained by Kasten-Sportes et al. (22) , who also obined T cell lines only when GVHD was confirmed. Recently, reports (32) (33) (34) The role of HLA-DP antigens in GVHD is controversial (28) (29) (30) . Our data document the presence of specific CD4+ anti-DP T cells (against DP1O1 for patient 1 and DP401 for patient 2) at the site of a GVHD lesion 33 and 23 d after BMT, respectively. Together with recent evidence of a significant correlation between HLA-DP matching and a favorable outcome (30) , this underscores the importance of extensive HLA typing before grafting. These results also raise 2 major questions regarding the nature ofthe Ag-presenting cells and the Ag itself:
First, are the antigen-presenting cells Langerhans cells or keratinocytes?
Langerhans cells are considered likely to induce strong immunization against MHC class II molecules. Although these cells are usually no longer detectable in the skin at the time of biopsy (3 1 ) and were not detected in the case ofpatient 1, they may still be present in small numbers, as suggested by previous Table I. 18
Gaschet et al. Table 1 .
Secondly, what is responsible for the tissue specificity ofthe immune response? HLA disparity is related to the appearance and intensity of the immune response during GVHD. However, tropism to epithelia is generally associated with GVHD. Consequently, the mechanism underlying this specificity should be at work in the different circumstances observed. As indicated by Parfray et al. ( 18) in a rat model, class-Il antigen alone cannot account for the specificity of tissue injury because a high number of nonepithelial cells expressing HLA class-II in many tissues is not affected by GVHD. These authors suggest that allogeneic T cells may have a higher affinity for class II antigens when these molecules are complexed to epithelial-specific antigens. The arguments in favor of this possibility are that T cells directed at nonphysiologically presented autologous peptides are not deleted (37) , that MHC molecules on different cell types may not be recognized in the same way by T cells ( 17, 38, 39) , and that MHC class-II peptides involved in allorecognition may originate from exogenous proteins (40) . However, this hypothesis does not fit very well with the data presented in this article because specificity studies were performed using BLCL cultured in the presence of 10% FCS. Nevertheless, the cytotoxic activity we observed was relatively low although specific (e.g., never > 35% at a 50:1 effector/target ratio through six independent determinations for clone M 15). It is possible that the affinity of these T cells for their target would have been much better if the HLA molecules recognized were loaded with the "right" peptide. The T cells clones described here should allow us to clarify this point, which is essential to a clear understanding of the role of TCR target interaction in determining tissue specificity during GVHD. If TCR specificity is not the reason for GVHD tissue specificity, other putative candidates such as homing-associated adhesion molecules differentially expressed on various T cell subsets might be considered. In this view, mucosal and cutaneous lymphocyte-associated antigens (MLA or CLA antigens) (41, 42) would be the best candidates.
